rxstat › Shortages › Almotriptan

Almotriptan (Axert) shortage status

Partial shortage

Source: Health Canada shortage reports · Updated Sep 29, 2026

Some Almotriptan products are in shortage in Canada (1 of 10 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Feb 9, 2027.

A triptan used to treat migraine headaches.

Products affected
1 / 10
In shortage since
Sep 28, 2026
Est. full return
Feb 9, 2027
Reports on file
25
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Book a pharmacist appointment
Need your prescription switched?
If your product stays unavailable, an online doctor can assess your situation and prescribe an alternative.
See a doctor online

Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Active shortage
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · since Sep 28, 2026, est. end Feb 9, 2027 · Disruption of the manufacture of the drug.
Active shortage
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · since Sep 28, 2026, est. end Feb 9, 2027 · Disruption of the manufacture of the drug.
Resolved
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · ended Jan 26, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOZ ALMOTRIPTAN
12.5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02405334 · ended May 4, 2026 · Disruption of the manufacture of the drug.
Discontinued
TEVA-ALMOTRIPTAN
12.5MG · TABLET · TEVA CANADA LIMITED
DIN 02434849
Resolved
TEVA-ALMOTRIPTAN
12.5MG · TABLET · TEVA CANADA LIMITED
DIN 02434849 · ended Jun 16, 2025 · Disruption of the manufacture of the drug.
Resolved
MYLAN-ALMOTRIPTAN
6.25MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398435 · ended Mar 22, 2024 · Shortage of an active ingredient.
Resolved
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · ended Mar 20, 2024 · Shortage of an active ingredient.
Resolved
TEVA-ALMOTRIPTAN
12.5MG · TABLET · TEVA CANADA LIMITED
DIN 02434849 · ended Jun 20, 2023 · Disruption of the manufacture of the drug.
Resolved
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · ended Mar 22, 2022 · Shortage of an active ingredient.
Resolved
MYLAN-ALMOTRIPTAN
6.25MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398435 · ended Mar 22, 2022 · Shortage of an active ingredient.
Resolved
ALMOTRIPTAN
12.5MG · TABLET · SANIS HEALTH INC
DIN 02466821 · ended Sep 6, 2019 · Disruption of the manufacture of the drug.

Showing 12 of 25 reports. All reports are on file with Health Canada.

What's happening

Almotriptan is currently affected by an active shortage report filed with Health Canada by MYLAN PHARMACEUTICALS ULC.

The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.

If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.

Almotriptan is classified under “ANTIMIGRAINE PREPARATIONS” (ATC N02CC).

Recent changes

Common questions

What is Almotriptan used for?

A triptan used to treat migraine headaches.

When will Almotriptan be back in stock in Canada?

The latest manufacturer estimate is Feb 9, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.

Why is Almotriptan in shortage?

See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Possible alternatives in the same class (antimigraine preparations)

Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.

Dihydroergotamine No current shortage Frovatriptan (Frova) No current shortage Galcanezumab (Emgality) No current shortage Naratriptan (Amerge) No current shortage Eletriptan (Relpax) Partial shortage 2 of 18 reported products affected · est. return Nov 10, 2026 Pizotifen (Sandomigran Ds) Partial shortage 1 of 1 reported products affected · est. return Dec 12, 2026

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.